Nov 9, 2026 · 29 min
Biotech investors weigh obesity, RAS drugs and Moderna catalysts
121 - Breaking Biotech Week End Wrap Up - Nov 7 , 2026
The episode tests whether three major biotech stories justify their valuations as markets absorb volatility and await pivotal clinical updates.
- 1A rumored AstraZeneca acquisition would value Rhythm’s rare-obesity franchise against ambitious expansion plans and upcoming clinical catalysts.
- 2Revolution Medicines’ RassonQ launch exceeded early expectations, strengthening the case for a durable multi-cancer franchise despite valuation and spending risks.
- 3Moderna’s stronger quarter rests partly on international COVID sales, while investors remain focused on oncology and rare-disease readouts.
Don't miss
Revolution Medicines reported $197.6 million in RassonQ revenue after only about five weeks on the market, prompting a reassessment of its commercial trajectory.
The brief
A sharp market sell-off and rebound set the backdrop, with technology, data-center stocks, biotech indices, tools companies, diagnostics and AI-related biotechs all under pressure while XBI remained relatively strong year to date.
The rumored AstraZeneca acquisition of Rhythm Pharmaceuticals puts rare-obesity economics under scrutiny: Imcivree’s severe-disease focus, potential expansion and clinical catalysts must support a roughly $10 billion valuation.
Revolution Medicines delivered $197.6 million in RassonQ revenue after about five weeks, but the launch’s durability depends on uptake, stocking effects, competition and expansion across pancreatic, colorectal and lung cancers.
Moderna reported higher revenue, profitability, increased guidance and more cash, yet the investment case still turns on intismeran oncology data and mRNA-3927’s rare-disease potential.
The episode closes on Moderna’s analyst day, renal-cell-carcinoma data and propionic-acidemia readouts as the next tests of an ambitious narrative carrying meaningful execution risk.
What was said on this episode
19 statements · 16 positive · 2 negative · 1 neutral
Rare-disease drugs can command higher prices
“But because it's a rare disease, they can also garner a higher price.”
Listen at 5:04
Setmelanotide reduced BMI substantially more than placebo in the trial
“the treatment group with set melanotide was able to lower their BMI by 16.5% compared with placebo that gained BMI change at 3.3%.”
Listen at 7:55
Rhythm’s franchise could reach approximately $3.5 billion in peak sales
“we're looking at a total potential peak sales of about $3.5 billion with this franchise.”
Listen at 9:16
AstraZeneca’s rumored Rhythm acquisition appears expensive
“it seems like it's kind of expensive in my opinion”
Listen at 9:31
Rhythm’s next-generation agonists could improve compliance and value
“It'll help with patient compliance and add to the value as well.”
Listen at 10:49
Early RM718 data in Prader-Willi syndrome appears encouraging
“the early data in that patient population looks okay. And so it seems like it should work out for them”
Listen at 11:20
Big-pharma acquisition premiums signal favorable conditions for biotech
“Big Pharma is willing to pay a pretty generous premium on a company that still has regulatory risk as well as some clinical risk in it bodes well, obviously, for the sector.”
Listen at 12:08
Q4 revenue is needed to estimate RassonQ’s sustainable run rate
“We'll have to see what Q4 looks like in terms of revenue to be able to come up with a more reasonable steady state run rate”
Listen at 15:04
RassonQ appears effective across different RAS-mutant cancers
“it seems to work particularly well in different RAS mutant cancers.”
Listen at 15:53
RassonQ treatment doubled median survival versus chemotherapy
“The Daraxonix Recib group median overall survival was 13.2 months compared with chemotherapy at 6.7 months.”
Listen at 16:10
RassonQ’s expanded indications could produce approximately $10 billion peak sales
“adding lung and colorectal cancer probably puts the peak sales somewhere at $10 billion.”
Listen at 17:16
Revolution Medicines appears to have a first-mover advantage
“it seems like RedMed has the advantage of being first to market with these treatments”
Listen at 19:55
International COVID vaccine sales drove most of Moderna’s revenue increase
“Most of the revenue, though, is due to the increase in international COVID vaccine sales.”
Listen at 22:29
Positive RCC data would support intismeran efficacy beyond melanoma
“if it's positive, it's going to contribute to this narrative that intusmerion doesn't just work in melanoma, but also in RCC.”
Listen at 23:30
Intismeran RCC data could materially move Moderna’s stock
“that's going to be a big mover for the stock, in my opinion.”
Listen at 23:48
Moderna’s lipid-nanoparticle technology is well suited to propionic acidemia
“Moderna's technology is uniquely suited for this”
Listen at 24:55
Positive propionic-acidemia results could expand Moderna into rare diseases
“if they see a positive effect here, then they're also going to be able to include rare disease into their franchise.”
Listen at 25:30
mRNA-3927 has a substantial effect in propionic-acidemia patients
“the effect of mRNA 3927, which is their drug, has a big impact in these patients.”
Listen at 26:44
Moderna’s high valuation depends on an unrealized, uncertain future
“the company's got such a high valuation now on a reality that doesn't quite exist yet and might never exist.”
Listen at 27:50
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.